Citigroup
NTLA icon

Citigroup’s Intellia Therapeutics NTLA Stock Holding History

Citigroup’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100
Closed -$3.16K – 5809
2023
Q3 		$3.16K Buy
+100
New +$3.88K ﹤0.01% 4843
2022
Q4 		– Sell
-25,000
Closed -$1.4M – 5898
2022
Q3 		$1.4M Buy
+25,000
New +$1.55M ﹤0.01% 2450
2020
Q2 		– Sell
-2,800
Closed -$34K – 7630
2020
Q1 		$34K Sell
2,800
-1,200
-30% -$16.2K ﹤0.01% 6321
2019
Q4 		$59K Sell
4,000
-2,200
-35% -$30.6K ﹤0.01% 6182
2019
Q3 		$83K Sell
6,200
-1,500
-19% -$23.9K ﹤0.01% 5798
2019
Q2 		$126K Buy
7,700
+5,400
+235% +$84.9K ﹤0.01% 5655
2019
Q1 		$39K Sell
2,300
-7,500
-77% -$112K ﹤0.01% 6540
2018
Q4 		$134K Sell
9,800
-500
-5% -$9.29K ﹤0.01% 5407
2018
Q3 		$295K Buy
10,300
+2,200
+27% +$64K ﹤0.01% 4857
2018
Q2 		$222K Buy
8,100
+400
+5% +$9.69K ﹤0.01% 4956
2018
Q1 		$162K Buy
+7,700
New +$189K ﹤0.01% 5174

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Citigroup's NTLA Position: Q2 2026 in Review

Citigroup increased its Intellia Therapeutics (NTLA) stake by 535% in Q2 2026, buying an estimated $2.75M and bringing the position to 233,257 shares worth $3.95M. The position accounts for ﹤0.01% of the portfolio, ranked #2349.

Citigroup first reported a position in NTLA in Q2 2016 and has held it in 40 quarters since. The position peaked at $24.6M in Q1 2022. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Citigroup held 233,257 shares of Intellia Therapeutics worth $3.95M as of Q2 2026.
  • Citigroup bought 196,500 Intellia Therapeutics shares in Q2 2026, an estimated $2.75M.
  • Intellia Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2349 holding.
  • Citigroup first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 40 quarters since.
  • Citigroup's Intellia Therapeutics position peaked at $24.6M in Q1 2022.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.